Filing Flows

Filing Flows › Companies › Vitro Biopharma › Cash flow

Vitro Biopharma cash flow, quarter by quarter

Latest: Q3 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$2.0M in Q3 FY26 · −$4.3M over twelve months

Operating cash flow−$1.9M
Capital spending−$129K
Free cash flow−$2.0M

Analysis

In Q3 FY26, Vitro Biopharma generated −$1.9M of operating cash flow and spent $129K on capital projects, leaving free cash flow of −$2.0M. That is $1.3M less than in Q3 FY25 (−$681K).

Over the twelve months to Jul 31, 2026, operating cash flow was −$4.2M; the largest uses were operating cash flow ($4.2M), capital spending ($167K), net borrowing (+) / repaid (−) ($16K); besides operations, cash came from shares issued ($9.1M), other financing ($883K); the cash balance rose by $5.6M.

Operating cash flow was −$1.9M against net income of −$8.5M. The largest differences: payables −$779K, stock-based pay +$256K, inventory −$157K.

Free cash flow

Vitro Biopharma: free cash flow by quarterVitro Biopharma: free cash flow by quarter−$954KQ4 FY24−$428KQ1 FY25−$690KQ2 FY25−$681KQ3 FY25−$742KQ4 FY25−$1.1MQ1 FY26−$428KQ2 FY26−$2.0MQ3 FY26
Operating cash flow less capital spending.
Vitro Biopharma: operating cash flow against capital spendingVitro Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$954K$0Q4 FY24−$428K$0Q1 FY25−$690K$0Q2 FY25−$681K$0Q3 FY25−$738K$4KQ4 FY25−$1.1M$0Q1 FY26−$428K$0Q2 FY26−$1.9M$129KQ3 FY26
Latest (Q3 FY26): Operating cash flow −$1.9M, Capital spending $129K.

Capital allocation, year by year

Vitro Biopharma: where the cash came from (up) and went (down), by fiscal yearVitro Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY15: Operating cash flow −$100KFY15: Net borrowing −$21KFY15FY22: Operating cash flow −$2.2MFY22: Net borrowing −$210KFY22: Capital spending −$310KFY22FY23: Operating cash flow −$2.0MFY23: Net borrowing −$135KFY23: Capital spending −$121KFY23FY24: Operating cash flow −$3.2MFY24: Net borrowing −$127KFY24FY25: Operating cash flow −$2.5MFY25: Net borrowing −$4.4MFY25: Shares issued $700KFY25: Capital spending −$5K$700KFY25
Over these 5 years operating cash flow totalled −$10.1M; the largest uses were operating cash flow ($10.1M) and net borrowing ($4.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$5.7M
Debt$2.2M
Net cash$3.5M
Due within a year$594K
Cash runway16 months

Vitro Biopharma is burning cash: its operations consume cash, a free cash flow of −$4.3M a year at the current rate against $5.7M of cash and investments: a runway of about 16 months; $594K of debt also comes due within a year, which the cash covers before any new financing.

Vitro Biopharma: debt maturities by year (FY25)Vitro Biopharma: debt maturities by year (FY25)$594KYear 1$8.4MYear 2$1.7MYear 3$2.0MYear 5
Principal due in each year as disclosed in the annual report, against $5.7M of cash and investments now.

Where the cash came from and went

Vitro Biopharma: sources (+) and uses (−) of cash, Q3 FY26Vitro Biopharma: sources (+) and uses (−) of cash, Q3 FY26Shares issued$7.7MCash drawn (+) / kept (−)−$5.6MOperating cash flow−$1.9MCapital spending−$129KOther investing−$5KNet borrowing (+) / repaid (−)−$2KOther financing$1K
Vitro Biopharma: sources (+) and uses (−) of cash, TTM to Q3 FY26Vitro Biopharma: sources (+) and uses (−) of cash, TTM to Q3 FY26Shares issued$9.1MCash drawn (+) / kept (−)−$5.6MOperating cash flow−$4.2MOther financing$883KCapital spending−$167KNet borrowing (+) / repaid (−)−$16KOther investing−$14K

From profit to cash

Vitro Biopharma: net income to operating cash flow, Q3 FY26Vitro Biopharma: net income to operating cash flow, Q3 FY26Net income−$8.5MDepreciation & amortization$26KStock-based pay$256KReceivables−$29KInventory−$157KPayables−$779KAccrued liabilities−$44KOperating cash flow−$1.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 FY25251362276-2115
Q4 FY2424841137-1030

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 FY26−$1.9M−$129K−$2K$7.7M−$5.6M−$2.0M
Q2 FY26−$428K—−$3K$100K$370K−$428K
Q1 FY26−$1.1M—−$5K$1.0M$111K−$1.1M
Q4 FY25−$738K−$4K−$3K$300K−$429K−$742K
Q3 FY25−$681K—−$3K—$23K−$681K
Q2 FY25−$690K———−$84K−$690K
Q1 FY25−$428K—−$754K—$458K−$428K
Q4 FY24−$954K—−$27K—$972K−$954K

Vitro Biopharma: income statement and cash flow

Vitro Biopharma, Q3 FY26: revenue $570K (-6% year over year), operating margin -220.5%. The chart follows the revenue to costs, profit and cash.

Vitro Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.